Literature DB >> 33462790

Viral protein R polymorphisms in the pathogenesis of HIV-associated acute ischaemic stroke: a case-control study.

Kate McMullen1, Kathleen Bateman2, Alan Stanley2, Marc Combrinck3, Susan Engelbrecht4, Alan Bryer2.   

Abstract

HIV-1 viral proteins have been implicated in endothelial dysfunction, which is a major determinant of ischaemic stroke risk in HIV-infected individuals. Polymorphisms in HIV-1 viral protein R (Vpr) may alter its potential to promote endothelial dysfunction, by modifying its effects on viral replication, reactivation of latent cells, upregulation of pro-inflammatory cytokines and infection of macrophages. We analysed Vpr polymorphisms and their association with acute ischaemic stroke by comparing Vpr signature amino acids between 54 HIV-infected individuals with acute ischaemic stroke, and 80 age-matched HIV-infected non-stroke controls. Isoleucine at position 22 and serine at position 41 were associated with ischaemic stroke in HIV. Individuals with stroke had lower CD4 counts and CD4 nadirs than controls. These polymorphisms are unique to individuals with stroke compared to South African subtype C and the control group consensus sequences. Signature Vpr polymorphisms are associated with acute ischaemic stroke in HIV. These may increase stroke risk by promoting endothelial dysfunction and susceptibility to opportunistic infections. Therapeutic targeting of HIV-1 viral proteins may present an additional mechanism of decreasing stroke risk in HIV-infected individuals.

Entities:  

Keywords:  HIV; Stroke; Viral protein R

Mesh:

Substances:

Year:  2021        PMID: 33462790     DOI: 10.1007/s13365-020-00936-y

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  1 in total

1.  Prevalence and Characteristics of HIV-Associated Stroke in a Tertiary Hospital Setting in South Africa.

Authors:  Craig Corbett; Naeem Brey; Richard D Pitcher; Suzanne O'Hagan; Tonya M Esterhuizen; Felicia C Chow; Eric H Decloedt
Journal:  Neurology       Date:  2022-06-03       Impact factor: 11.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.